Evidence map›Paper›PMID 42150762›Full record

ArticleEuropean journal of haematology2026

Condensed vs. Standard Step-Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma.

Grace Elsey, James A Davis, Kelley Julian, Rebecca Gonzalez, Jordan Snyder, Mikhaila Rice, Victoria R Nachar, Jessica McElwee, Shebli Atrash, Christopher Cahoon and 15 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Grace ElseyLevine Cancer Institute, Charlotte, North Carolina, USA.
James A DavisHollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0001-7978-1652
Kelley JulianHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Rebecca GonzalezMoffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0003-0024-0699
Jordan SnyderUniversity of Kansas Cancer Center, Westwood, Kansas, USA.
Mikhaila RiceTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
Victoria R NacharUniversity of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
Jessica McElweeLevine Cancer Institute, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0002-9756-5360
Shebli AtrashLevine Cancer Institute, Charlotte, North Carolina, USA.
Christopher CahoonHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Baylee BryanHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Douglas W SborovHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Katelynn GrangerHollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, USA.
Matthew WarrickHollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, USA.
Anthony DominickHollings Cancer Center, The Medical University of South Carolina, Charleston, South Carolina, USA.
Doris K HansenMoffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0002-9813-3578
Ariel Grajales-CruzMoffitt Cancer Center, Tampa, Florida, USA.
Zahra MahmoudjafariUniversity of Kansas Cancer Center, Westwood, Kansas, USA.
Joslyn RudoniTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-7143-4063
Jonathan KissamTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
Megan VinceTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
Jack KhouriTaussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-2473-6528
Iman AhmedUniversity of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
Matthew PiankoUniversity of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
Donald C MooreLevine Cancer Institute, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0001-5629-9505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) between two different step-up dosing (SUD) schedules with talquetamab, the standard SUD schedule of Days 1, 4, 7, and 10 and a condensed SUD schedule of Days 1, 3, 5, and 7.

methodsWe conducted a multicenter retrospective study across seven academic medical centers in the United States and included patients who received talquetamab for the treatment of relapsed/refractory multiple myeloma. The incidence and grade of severity of CRS and ICANS were compared between patients receiving the standard SUD schedule and the condensed SUD schedule.

resultsA total of 144 patients were included in our analysis; 33 received the standard SUD schedule and 111 received the condensed SUD schedule. The incidence of CRS (76% vs. 56%; p = 0.101) and ICANS (9% vs. 16%; p = 0.41) was similar between the standard and condensed SUD cohorts. There was no significant difference in the severity of CRS and ICANS between both cohorts.

conclusionShortening the interval between talquetamab SUDs appears feasible and well-tolerated in routine clinical practice.

Indexed as

Multiple MyelomaAgedAntibodies, BispecificCytokine Release SyndromeDrug Administration ScheduleFemaleHumansMaleMiddle AgedNeurotoxicity SyndromesRecurrenceRetreatmentRetrospective StudiesTreatment OutcomeAntibodies, Bispecifictalquetamabbispecific antibodycytokine release syndromemultiple myelomatalquetamab

Identifiers

PMID42150762
PMCPMC13542843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.